EcoDrugPlus

Potassium Inwardly Rectifying Channel Subfamily J Member 3

Ensembl ID : ENSG00000162989
Gene: KCNJ3
Gene Synonyms: GIRK1,KGA,KIR3.1
1 APIs:
11 Enzyme and pathways 7 Cross references
229 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Potassium Inwardly Rectifying Channel Subfamily J Member 5

Ensembl ID : ENSG00000120457
Gene: KCNJ5
Gene Synonyms: CIR,GIRK4,KATP1,KIR3.4,LQT13
1 APIs:
11 Enzyme and pathways 9 Cross references
213 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Potassium Two Pore Domain Channel Subfamily K Member 2

Ensembl ID : ENSG00000082482
Gene: KCNK2
Gene Synonyms: K2P2.1,TREK-1
5 APIs:
7 Enzyme and pathways 7 Cross references
284 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Potassium Two Pore Domain Channel Subfamily K Member 3

Ensembl ID : ENSG00000171303
Gene: KCNK3
Gene Synonyms: K2P3.1,TASK,TASK-1,TASK1
6 APIs:
7 Enzyme and pathways 8 Cross references
202 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Potassium Two Pore Domain Channel Subfamily K Member 9

Ensembl ID : ENSG00000169427
Gene: KCNK9
Gene Synonyms: K2P9.1,TASK-3,TASK3
6 APIs:
7 Enzyme and pathways 9 Cross references
215 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Potassium Voltage-Gated Channel Subfamily A Member 5

Ensembl ID : ENSG00000130037
Gene: KCNA5
Gene Synonyms: HK2,HPCN1,KV1.5
1 APIs:
6 Enzyme and pathways 8 Cross references
170 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Potassium Voltage-Gated Channel Subfamily D Member 3

Ensembl ID : ENSG00000171385
Gene: KCND3
Gene Synonyms: KSHIVB,KV4.3,SCA19,SCA22
1 APIs:
6 Enzyme and pathways 9 Cross references
261 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Potassium Voltage-Gated Channel Subfamily H Member 2

Ensembl ID : ENSG00000055118
Gene: KCNH2
Gene Synonyms: ERG1,HERG,KV11.1,LQT2
7 APIs:
6 Enzyme and pathways 9 Cross references
253 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Potassium Voltage-Gated Channel Subfamily Q Member 2

Ensembl ID : ENSG00000075043
Gene: KCNQ2
Gene Synonyms: BFNC,EBN,EBN1,ENB1,HNSPC,KCNA11,KV7.2
1 APIs:
8 Enzyme and pathways 8 Cross references
250 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Potassium Voltage-Gated Channel Subfamily Q Member 3

Ensembl ID : ENSG00000184156
Gene: KCNQ3
Gene Synonyms: EBN2,KV7.3
1 APIs:
8 Enzyme and pathways 8 Cross references
193 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Potassium Voltage-Gated Channel Subfamily Q Member 5

Ensembl ID : ENSG00000185760
Gene: KCNQ5
Gene Synonyms: KV7.5
1 APIs:
3 Enzyme and pathways 8 Cross references
200 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Presenilin 1

Ensembl ID : ENSG00000080815
Gene: PSEN1
Gene Synonyms: AD3,FAD,PS-1,PS1,PSNL1,S182
5 APIs:
36 Enzyme and pathways 9 Cross references
202 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).